SARC Clinical Trials: Past and Present
Below is a list of trials conducted by SARC, a brief description of the clinical trial, and whether or not the study is open to enrolling new patients.
|
STUDY # |
STUDY DESCRIPTION |
TYPE OF SARCOMA |
ACCEPTING NEW PATIENTS** |
|
|
Imatinib mesylate (gleevec) in patients with soft tissue and bone sarcomas: a multi-disciplinary trial |
Soft tissue and |
NO |
||
|
120-minute infusion gemcitabine v. 90-minute infusion Gemcitabine plus Docetaxel in unresectable soft tissue sarcoma. |
Unresectable |
NO |
||
|
Sequential gemcitabine followed by docetaxel for recurrent ewing's sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma |
Ewing's,Osteosarcoma and Chondrosarcoma |
NO |
||
|
Short course of neoadjuvant gleevec (imatinib mesylate) in dermatofibrosarcoma protuberans |
Dermatofibrosarcoma protuberans |
NO |
||
|
Adjuvant treatment of high risk leiomyosarcoma with gemcitabine/ docetaxel, followed by doxorubicin: a phase II multi-center trial |
Uterine leiomyosarcoma |
NO |
||
|
Neoadjuvant chemo-therapy in sporadic and nurofibromatosis type 1 associated high grade unresectable or metastatic potentially resectable malignant peripheral nerve sheath tumors |
Sporadic and neuro- fibromatosis associated with peripheral nerve sheath tumors |
NO |
||
|
Perifosine in patients with chemo-Insensitive sarcomas |
Chemo-insensitive sarcomas |
NO |
||
|
Dasatinib in advanced sarcoma |
Advanced sarcoma |
NO |
||
|
R1507 IGF1R, a recombinant human monoclonal antibody for the treatment of patients with recurrent or refractory ewing's sarcoma, and other soft tissue sarcomas |
Ewing's, Osteosarcoma, synovial, rhabdomyo-sarcoma and others |
NO |
||
|
AZD0530, a selective src kinase inhibitor, in patients w/recurrent osteosarcoma localized to the lung |
Osteosarcoma |
YES |
||
|
mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic & neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors |
Malignant peripheral nerve sheath tumors |
YES |
||
|
Dose escalation versus no dose escalation of Imatinib In metastatic GIST patients w/imatinib trough levels less than 1100 nanograms/mL. |
Gastro-intestinal stromal tumors |
NO |
||
|
Comparing the efficacy of Trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma |
Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade; some subtypes excluded. |
Recruitment Suspended |
||
|
TH-302 in combination with doxorubicin compared to doxorubicin to doxorubicin alone |
Soft tissue sarcoma |
YES |
||
|
OSI-906, an oral tyrosine kinase inhibitor, in patients with gastrointestinal stromal tumors |
Advanced wild-type gastrointestinal stromal tumors (GIST) |
YES |
**When a trial is not accepting new patients, this means the study enrollment has been completed.